← Back to Search

Anticoagulant

Rivaroxaban for Deep Vein Thrombosis ((RAMBLE) Trial)

Phase 2 & 3
Waitlist Available
Led By Jeffrey A Kline, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 2, and 3 months
Awards & highlights

Summary

This trial finds that apixaban is better than rivaroxaban at reducing menstrual blood loss in women with VTE or atrial fibrillation.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)
  • Menstruation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 2, and 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 2, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PBAC Scores
Secondary outcome measures
Hemoglobin Concentration
Number of Participants Who Crossed Over to Another Anticoagulant
Number of Participants Who Discontinued Planned Drug Administration
+5 more

Trial Design

2Treatment groups
Active Control
Group I: RivaroxabanActive Control1 Intervention
Group II: ApixabanActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
997 Previous Clinical Trials
1,095,575 Total Patients Enrolled
1 Trials studying Deep Vein Thrombosis
100 Patients Enrolled for Deep Vein Thrombosis
Jeffrey A Kline, MDPrincipal InvestigatorIndiana University
4 Previous Clinical Trials
1,333 Total Patients Enrolled
~2 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top